🇺🇸 FDA
Pipeline program

Palazestrant

OP-1250-302

Phase 3 small_molecule active

Quick answer

Palazestrant for Breast Cancer is a Phase 3 program (small_molecule) at Olema Pharmaceuticals with 3 ClinicalTrials.gov record(s).

Program details

Company
Olema Pharmaceuticals
Indication
Breast Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials